Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Featured News

    Giant Molecules as Antiviral Agents

    By Global Biodefense StaffNovember 9, 2015
    Giant Molecule to Block Receptors for Virus Transmission
    Share
    Facebook LinkedIn Reddit Email

    A European research collaboration has designed a “giant” molecule to inhibit cell infection by Ebola.

    12 fullerenes, each one endowed with 10 sugar moieties, connected to central fullerene, thus mimicking the presentation of carbohydrates surrounding the Ebola virus. Credit: N. Martín & B. Illescas / UCM.
    12 fullerenes, each one endowed with 10 sugar moieties, connected to central fullerene, thus mimicking the presentation of carbohydrates surrounding the Ebola virus. Credit: N. Martín & B. Illescas / UCM.

    Past studies had already demonstrated that the Ebola virus infection process starts when the virus reaches the cellular DC-SIGN receptor to infect the dendritic cells of the immune system.

    The research team formed thirteen fullerenes, covered by carbohydrates, to form the large molecule which block this DC-SIGN receptor receptor. The creation proved successful in blocking infection when tested with an artificial Ebola virus model.

    “Fullerenes are hollow cages exclusively formed by carbon atoms”, explains Nazario Martín, Professor of Organic Chemistry in the Universidad Complutense de Madrid and main author of the study. In this work, scientists have employed C60 fullerene, which is formed by 60 carbon atoms and has the shape of a truncated icosahedron, which resembles a soccer ball.

    These molecules decorated with specific carbohydrates (sugars) present affinity by the receptor used as an entry point to infect the cell and act blocking it, thus inhibiting the infection.

    Researchers employed an artificial Ebola virus by expressing one of its proteins, envelope protein GP1, responsible of its entry in the cells. In a model in vitro, this protein is covering a false virus, which is able of cell infection but not of replication.

    “We have employed a cell model previously described in our lab which consists in a cell line of human lymphocytes expressing DC-SIGN receptor, which facilitates the entry of the virus in Dendritic Cells”, points out Rafael Delgado, researcher of the Hospital 12 de Octubre, and one of the co-authors of the study.

    By blocking this receptor and inhibiting the virus infection, the authors think that the dissemination of the virus would decrease and the immune response increase, but this idea has still to be developed with in vivo studies.

    The team has achieved an unprecedented success in fullerene chemistry and dendritic growth: connecting in one synthetic step twelve fullerene units, each with ten sugars, to other central fullerene, creating a globular superstructure with 120 sugar moieties on its surface, “this is the fastest dendrimeric growth developed in a laboratory up to now” says Beatriz Illescas, Professor in the UCM and co-author of the work.

    According to scientists, the results highlight the potential of these giant molecules as antiviral agents. “This work open the door to the design and preparation of new systems to inhibit the pathogens infection in cases where the current therapies are not effective or are inexistent, as occurs with the ebolavirus”, clarifies Martín.

    After these experiments on the cellular level, researchers will study the behavior of these systems in animal models, starting with mice. “We will study, on the one hand, the pharmacokinetics and, on the other, the antiviral activity in vivo” explains Javier Rojo, researcher of the Instituto de Investigaciones Químicas del CSIC and other of the authors of the study. Once the most effective compound has been identified, studies using the true Ebola virus could be carried out.

    Read the study at Nature Chemistry: Synthesis of giant globular multivalent glycofullerenes as potent inhibitors in a model of Ebola virus infection. DOI: 10.1038/nchem.2387.

    Animal Models Antivirals Ebola
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – Nov 8, 2015
    Next Article Human Dark Proteome Initiative Launches

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy